Manhattan Genomics

Manhattan Genomics is a precision medicine company specializing in high-resolution genomic diagnostics and liquid biopsy technologies. The company's core focus is the MG-X platform, which enables the detection and analysis of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from simple blood draws. By providing detailed molecular insights into a patient's cancer, Manhattan Genomics aims to facilitate personalized treatment strategies and real-time monitoring of disease progression. Their services cater to clinical researchers and oncologists seeking to improve patient outcomes through non-invasive diagnostic tools. The company's technology emphasizes single-cell analysis to capture the full heterogeneity of tumors.